A novel medium-throughput biological assay system for HTLV-1 infectivity and drug discovery by Fattahi Abdizadeh, Mojtaba et al.
   
 
Iranian Journal of Basic Medical Sciences 
 
ijbms.mums.ac.ir 
 
 
 
A novel medium-throughput biological assay system for HTLV-1 
infectivity and drug discovery 
 
Mojtaba Fattahi Abdizadeh 1, 3, 4, Manoochehr Makvandi 2, Alireza Samarbafzadeh 3, Kayhan 
Azadmanesh 4*  
 
1 Department of Microbiology, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran  
2 Infectious and Tropical Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran        
3 Department of Virology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran 
4 Virology Department, Pasteur Institute of Iran, 69 Pasteur Ave 1316943551. Tehran, Iran 
 
A R T I C L E  I N F O  A B S T R A C T 
Article type: 
Original article 
  
Objective(s): Here, a reporter cell line containing two reporter vectors were developed, in order to monitor 
the Human T-Lymphotropic Virus type1(HTLV-1) infectivity and the cell viability simultaneously. 
Materials and Methods: The reporter cell line was constructed by stably transfected baby hamster's 
kidney cell line (BHK-21), with the genomes expressing two different reporters in separate plasmids. 
The first reporter gene is transactivated by the HTLV-1 tax protein, while the second reporter is 
continuously expressed when introduced into a mammalian cell. In order to show its functionality, the 
effect of the drug mix on HTLV-1 was assayed by this system and was compared to the results obtained 
by other methods. 
Results: HTLV-1 reporter cell line was found to produce high level of luciferase when co-cultured with 
MT-2 and Hut-102 cells but not with Jurkat cell. Moreover, the combination therapy against HTLV-1 can 
reduce luciferase expression of the cell when co-cultured with MT-2 and Hut-102 comparable to the 
ELISA (R=0.932, P-value =0.002). In addition, the results revealed the superiority of the present system 
over the molecular methods. 
Conclusion: The results demonstrated that the biological assay system is a beneficial tool for the 
medium-throughput anti-HTLV-1 drug screening and inhibitory effect. 
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Introduction 
The diseases associated with of HTLV-1 were 
known and introduced in Iran long time before the 
discovery of the virus itself by Bernard Poiesz in 1980 
(1-3). 
HTLV-1; Which stands for: Human T-cell Lympho-
tropic  Virus  type  1, is a public health threat in endemic 
areas, with more than 20 million infected people 
worldwide. In some foci like Sabzevar and Mashhad (2 
major cities of  Khorasan Province  in  Iran), the 
prevalence is up to 3% (4-8). Unfortunately, despite the 
considerable progress in HTLV-1 researches over the 
past three decades,  still there isn't an available Food and 
Drug Administration (FDA), approved medicine or 
beneficial tool for anti HTLV-1drug screening (8-11). 
The quantitative assessment of the virus and its infectivity 
is an important step for various basic and clinical studies 
as well as the analysis of drug susceptibility. HTLV-1 has 
the non-cytolytic and cell associated properties in cell 
culture (12). Thus, available classical virological methods 
such as: plaque assays are not usually used for  the quanti- 
tation of HTLV-1 infectivity. In other hand, the other 
techniques i.e. ELISA and PCR-based assays are either 
expensive or do not allow accurate quantitation of the 
number of the infectious viral titer over time (13-15). 
Hence, the unavailability of a rapid, economic, high-
throughput assay for titrating HTLV-1, has hampered 
the efforts both to screen the new compounds and 
also the systematic analytical study on HTLV-1(16). 
The reporter cell systems are more commonly used in 
the drug susceptibility assays and the detection of 
virus infectivity (12, 17-20). Different reporter cells 
have been reported for HTLV-1 in the literature, such 
as: pA18G-BHK-21 cells (21), H1GFP cells (22) and 
H9/K30luc cells (16). All these cell lines carry a 
reporter gene regulated by the HTLV-1 long terminal 
repeat (LTR) promoter, inducing them to produce the 
reporter protein while they are infected with HTLV-1. 
Even though pA18G-BHK-21 cells with β- galactosidase 
reporter and H1GFP cells with green fluorescent 
protein can detect viral infection by some degrees. It 
seems that H9/K30luc cells with the third generation- 
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luciferase reporter vector had a higher sensitivity as 
compared to them (16).  
To facilitate the analysis and monitoring the HTLV-1 
infection, a unique HTLV-1 reporter cell line with two 
reporter vectors was designed in this research. At first, 
these two reporter vectors were constructed and tested, 
and then BHK-21 cell was stably transfected by them. 
The suitability of the cell line in measuring the virus 
replication was tested by using the co-culture with 2 
different HTLV-1 producing cell lines. Finally the system 
was used to evaluate the effect of the drugs combination 
on the HTLV-1 replication. 
 
Materials and Methods 
Plasmids and constructs  
pGL4.17 (Promega, USA), pEGFP-N1 vector (Clontech 
CA, USA) and pCDNA3.1Hyg+ mammalian expression 
vectors (Invitrogen, USA) were purchased. pCDNA3.1TAX 
Hyg+ (23) was used for the induction of Luc expression. 
Two different reporter plasmids, pGL4LTRLuc and 
pCDNA3.1 SV40-EGFP Hyg+, were constructed (Figures 
1b, 1c). The first vector has been previously described 
(24). To sum up, HTLV-1 LTR promoter containing three 
tax respond elements (TRE I, II and III), was cut out from 
pUCLTRlacz (25) and then it was subcloned into the MCS 
site of plasmid pGL4.17 (Promega, USA), at the upstream 
of the Luciferase reporter gene. The second reporter vector, 
pCDNA3. 1SV40-EGFP Hyg+, was constructed by cloning 
of the SOEing Plymerase Chain Reaction (PCR) product, 
SV40 promoter linked to EGFP (SV40-EGFP), into 
pCDNA3.1Hyg+, to express the EGFP continuously when 
it is introduced into a mammalian cell. Firstly, SV40 
promoter from pCDNA3.1Hyg+  and fragment of pEGFP-
N1 containing the EGFP were amplified by PCR using the 
following set of primers:  
SV40FWD =5' CAAGATCTGGTTAAAAAATGAGCTGA-
TTTA 3', SV40Rev =5'TTGCTCACCATCACGT GCTGATCA-  
GAT 3'. 
EGFP FWD=5' GTGATGGTGAGCAAGGGCGAG3', EGFP-
Rev= 5' TGGACAAACCACAACTAGAATGCAGTG 3'. 
Then, the integration of SV40 promoter was done 
using the Touchdown PCR protocol by the SV40FWD 
and EGFP Rev as forward and reverse primers at            
the EGFP gene upstream (Figure 1a). After that, it (SV40-
EGFP) was cloned, simultaneously when the CMV 
promoter was removed in pCDNA3.1+Hyg between the 
XbaI- BglII sites (Thermo Fisher Scientific, LithuaniaLtd). 
Once the selected colonies were grown in the Luria-
Bertani broth (LB, Himedia) overnight, the recombinant 
vector was purified by the QIAGEN Plasmid Mini Kit 
(Qiagen, Germany).  
 
Cell lines and culture 
Baby hamster kidney cells (BHK-21), which has 
demonstrated high susceptibility to HTLV-1 (Cat No: 
C107) was obtained from the National Cell Bank of 
Iran (Pasteur Institute of Iran, Tehran). BHK-21 cell 
line was grown in high-glucose Dulbecco’s modified 
Eagle’s medium (Gibco) supplemented with 10% heat 
inactivated fetal bovine serum (FBS), 100 units-100 
μg/ml/ml penicillin-streptomycin(PAA, austeria) and 
2 mM L-glutamine at 37 °C in 5% CO2. T-cell lines, 
HTLV-1-producer cell lines, MT-2  and HUT 102 cells 
(HTLV-1 producing CD4+human T-cell lines as effector 
cells) (26) and Jurkat (HTLV-1 infection free CD4+ T 
lymphocyte) were maintained in RPMI 1640 (PAA, 
Austeria) with the same supplements.  
 
Transient transfection and reporter expression evaluation 
The BHK-21 cell was plated at a density of 4 × 104 
cells per well in 48-well plates and allowed to grow 
overnight. 0.2 μg of pCDNA3.1SV40-EGFP Hyg+ plasmid 
was transfected into the BHK-21 cell using Polyfect 
(Qiagen, Hilden), according to the manufacturer’s 
instructions. 8 hrs after post-transfection, medium was 
replaced by fresh medium. Throughout 48 hr, EGFP 
expression was showed using fluorescent microscopy 
(Figure 2a).  
 
Establishment of the reporter cell line 
First stably transfection and clonal selection 
The BHK-21 cells were cultured at a density of 
5×105 cells per well in 6-well plates to reach a 
confluency of 70 percent and allowed to grow 
overnight. Six µg pCDNA3.1SV40-EGFP Hyg+ plasmid 
linearized with Bgl II digestion, was transfected into 
the BHK-21 cells using Polyfect (Qiagen, Hillden) 
according to the manufacturer’s recommendation. 
After transfection the plate was centrifuged 5 min at 280 
g. Four hr after post-transfection, the medium was 
replaced with fresh medium. Forty-eight hr after 
transfection, the cells were cultured in complete 
medium supplemented with 0.2 mg/ml Hygromycin 
(Hyg B) (Invivogen, USA). To obtain stable clones, during 
several weeks the Hyg-resistant colonies were isolated 
further by plating them at three rounds of limiting 
dilution (27) onto 96-well plates during several weeks. 
The single clones with no EGFP expression were 
removed. Several clones from remaining cells with high 
constitutive EGFP expression (Figure 2b) were stably 
transfected with pGL4LTRLuc. Before that correlation 
beetwen EGFP activity and cell viability was evaluated 
by flow cytometry using propidium iodide (PI) staining 
and dye exclusion method as described elsewhere (28). 
Besides, different expression was shown by two distinct 
clones (Figure 3a). Also the validity of using EGFP activity, 
to monitor reporter cell numbers, was evaluated by 
measuring EGFP activity in various numbers of cells and 
determining the correlation between EGFP activity and 
cell numbers using flourimeter (Biotek, USA). Reporter 
cells were plated into 96-well plates triplicate (3 wells 
for each test) at different density of cells from 10 ×10 3   
to 100×10 3 cells per well. And then they were assayed 
by flourimeter (Figure 3b). 
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Second stably transfection and clonal expansion 
(Selection of monoclonal populations from BHK-EGFP-
HTLVLTR luc) 
BHK-EGFP cells were plated and stably transfected 
with 5 µg linearized pGL4LTRLuc plasmid using            
the same procedure for the first transfection. Two 
days after transfection, the cells were cultured in 
complete medium containing 0.2 mg/ml hygromycin 
and 1 mg/ml geniticin (G418) (Invivogen, USA) for            
3-4 weeks. Stable colonies were isolated by culturing 
them at limited dilution in wells of a 96-well plate                
for three cycles. Subsequently several single clones             
of the G418-resistant colonies were taken under 
luciferase assay with following procedure. After seeding 
10 4 cells into 96-well plates for 24 hr, BHK-EGFP-HTLV-
1Luc cells were transfected with 0.2 μg Tax expression 
plasmid using Polyfect reagent (Qiagen, 493277090A012 
Germany).Transfection was normalaized as previously 
described. After additional 48 hr incubation, we per-
formed luciferase by using One Glo system assay (Promega-
Inc.) according to the manufacturer’s instructions onto a 
Synergy4 luminometer (Biotek, USA). The cells with high 
constitutive luciferase expression were removed. 
Furthermore 27 colonies were selected for the lowest 
background and high Luc expression upon co-culture 
with 104Hut-102 cells for 48 hr. 
 
Evaluating the sensitivity and of reporter cell line 
using different number of effector cell 
In order to evaluate the sensitivity of this system, 
a matrix including different numbers of effector cells 
(Hut-102, HTLV-1 producing cell) and reporter cell 
(BHK-EGFP-HTLVLTR-Luc cell) was prepared and           
co-cultured in a 96-well plate according to the Table-
1. In a similar experiment, a Jurkat cell, as negative 
viral control, was co-cultured with the reporter cell 
simultaneously. In addition, three non-co-cultured 
wells were considered for measuring background 
expression. The experiments were replicated in 
different days (in triplicate format). In all different 
experiments, similar conditions were applied for both 
cultivation of cells and measurement of Luciferase 
expression. 
 
A. Investigating the application of reporter cell in drug 
screening against HTLV-1 virus  
First, for determining toxicity of the medicines 
used in this study, a number of 2×104 reporter 
(reporter) cells were co-cultured with 3×104 Jurkat 
cells in duplicate format in a 24-well plate. It was then 
exposed to different densities of Arsenic trioxide (0.5, 
1, 1.5 and 2 μmol/ml; Sina Daru, Iran) and Interferon 
alpha 2 (500, 1000, 1500, 2000 Iu/ml; Pooyesh Daru, 
Pdferon, Iran) (29). After 72 hr, viability percentage 
of the cells was easily calculated, by using flow -
cytometry. This value was also computed in separated 
24-well plate cell culture for reporter and Jurkat cells 
with hemocytometer and 0.4% Trypan Blue solution 
(w/v). To implement cytometry, 1 μg/ml PI was 
added to the cells and viability and number of treated 
reporter and Jurkat cells versus control cells were 
studied, using control cells. Fluorescence expression 
in reporter cells was read in FL1 channel, and dead 
cells or cells in the final stage of apoptosis (the 
presence of PI in the cell) were read in FL3 channel. 
FloMax 2.7 was employed for analyzing the outputs. 
Subsequently, a number of 3×105 HuT-102 and 
MT2 cells were cultivated separately in a 6-well plate 
in RPMI1640 media, containing two pharmaceutical 
compositions, namely (As: 1 μmol/ml), (IFn: 1000 
Iu/ml), versus control media. After 72 hr, cells were 
counted and the number and percentage of their 
viability were determined. Then, 50 ul HuT-102 and 
MT2 were added (from control and treated cells, 
separately) to the reporter cell, cultivated the day 
before, in 96-well plate in triplicate format. EGFP and 
luciferase expression were measured after 60 hr. 
Then luciferase expression (the effect of medicine on 
the virus and effector cell) and EGFP expression (the 
effect of medicine on BHK-21 cell and its number) 
were calculated and modified using the following 
formula.  
Luc Test /EGFP Test/Luc control/EGFP control = 
Corrected luciferase expression 
 
A.1. Comparison between the luciferase expression level 
and the amount of produced p19 antigen, using ELISA  
After 72 hr exposure to the effector cells, in the 
presence or absence of pharmaceutical composition 
in the A-stage, sampling from cell culture supernatant 
media was done and ELISA for p19 antigen of HTLV-1 
was performed according to kit (ZeptoMetrix .Buffalo, 
NY). Next, it was read in ELISA reader at 450 nm 
wavelength. 
 
A.2. Comparison between luciferase expression and 
HTLV-I tax mRNA expression 
HuT-102 and MT2 cells were centrifuged (at 300g) 
in the A-stage after 72 hr. The supernatant was 
removed and washed three times with phosphate 
buffer. Total RNA was then extracted using RNXTM 
(Plus) (CinnaGen Inc.) according to its Protocol. After 
cDNA synthesis, using QuantiTect Reverse Transcrip-
tion Kit (Qiagen, Germany), Real-time PCR test was 
done, using HotTaq EvaGreen® qPCR Mix (CinnaGen 
Inc.) according to the following protocol, 1- Primery 
denaturation at 95 °C  for 10 min, 2- Contain 40 cycles 
with following steps:  3-Denaturation  at 95 °C for 10 
sec,  4- Extension at 60 °C for 60 sec, Melt curve: 55-
99 °C (with 1°C increase during every 5 sec) and with 
the presence of Tax gene specific primer: 
TaxF: 5´-GGATACCCAGTCTACGTGT-3´ 
TaxR: 5´-GAGCCGATAACGCGTCCATCG-3´ 
As internal control, GAPDH primer (housekeeping 
gene) was used (15). The Real-time PCR test was done 
by using Corbett (65HO). 
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Statistical analysis 
Statistical analysis was done with SPSS16.0, by using 
Pearson's correlation test, t-test and one-way ANOVA.  
 
Results  
The creation of pCDNA3.1+Hyg SV40-EGFP recombinant 
as the second vector 
By using the SOEing PCR, the integration of SV40 
promoter was done at the EGFP gene upstream. Then, 
it (SV40-EGFP) was cloned, at the same time when the 
CMV promoter was removed, in pCDNA3.1+Hyg between 
the XbaI- BglII sites. The SV40 promoter was selected             
due to its weaker performance to CMV, so the cell                    
line permanent EGFP expression could exert less potential 
negative effect on the activity of the first vector (pGL4L 
TRLuc) in the cell.  
The proper performance of the cloned SV40-EGFP 
segment was concluded by the transiently transfec-
tion of BHK-21 cells with the EGFP reporter vector 
and the observation of EGFP protein in the cell, after 
24 hr, using a fluorescence microscope. The proper 
performance of the luciferase reporter vector (pGL4-
LTR-Luc) was previously shown with the transiently 
transfer to the cell (26). 
 
 
 
 
(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
(c) 
 
 
Figure 1. (a) SOEingPCR; On the left, SV40-EGFP  fragment that was 
double digested between XbaI- BglII sites, and undigested SV40-
EGFP fragment can be seen on the second lane. Lane 3- 1 kb lambda 
marker bands, lane 4- amplified SV40 promoter from pCDNA3.1+Hyg 
containing 455 bp, lane 5- amplified EGFP gene from pEGFP-N1 
containing 948 bp. (b) and (c): structure of pGL4LTRLuc and pCDNA3.1 
SV40-EGFP Hyg+ vectors, respectively 
   
Establishing the BHK-EGFP-HTLVLTR-Luc reporter 
cell line 
In order to build this cell line, the EGFP expressing 
vector was stably transferred to the BHK-21 cell (Figure 
2b). The fluorescence expression level in different clones 
(Figure 3a) and the accuracy of relationship between the 
fluorescence expression and the number of cells have 
been shown (Figure 3b). In the second stage, the 
luciferase reporter gene carrying vector was stably 
transferred to the EGFP expressing clones. 
 
 
(a) 
 
 
 
(b) 
 
Figure 2. Fluorescence microscopic examination: Samples of (a) 
transiante and (b) stable transgenic EGFP expressing single-clones 
BHK-21, isolated by the serial dilution test,  can be seen 
.
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Figure 3. (a) Using a flowcytometer, a suspension was prepared from two clones, i.e. 11 (with lower fluorescence) and 5 (with higher 
fluorescence), and then the Propidium iodide (PI) color was added to it. The comparison between the PI colored, dead (FL3) cells and the 
two Fluorescence (FL1) producing cell populations are presented in the upper left panel. The fluorescence intensity of the first colon (close 
to the center of the curve), a base-10 logarithmic number, is lower than the second clone. The correlation between the EGFP activity and the 
cell viability of the cell suspension was conveniently evaluated by flow cytometry using PI staining comparing with the dye exclusion method 
as described elsewhere(28). (b) The linear relationship between the cell numbers and the expression level of EGFP (relative flourscence 
unit) is obvious where there are more than 20×103 cells. The experiment was done in triplicate format and the level of the expression was 
measured by the means of the flowmeter (85% sensitivity) 
 
 
 
With inducing 236 isolated single-clones by the 
Tax expression vector, the luciferase expression 
examination was done to obtain the best clone in 
terms of the expression level and the relative 
expression of luciferase. Unfortunately, in many 
colonies, either luciferase expression was turned off 
or the difference between the luciferase expression and 
the background expression levels was 2 times or less. 
Finally, 27 colonies with more than 2 times (up to 5.9x) 
expression were selected. Followed by the investigation 
of their reproducibility, two clones which exhibited 
strong transactivation of the integrated HTLV-1LTR-
Luc gene after co-cultured with HTLV-1infected cells 
were finally confirmed. Behind the reproduction and 
the stock preparation from these colonies, 
experiments were continued with one of them.  
 
Investigating the sensitivity of the reporter cell line 
luciferase expression based on the numbers of 
effector to reporter cells  
In order to obtain the expression level based on the 
cell and quantitative estimation, the induction effect of 
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different numbers of effector (HTLV-1 producer) on the 
reporter cells was used instead of using different virus 
numbers according to Table 1. Then the luciferase 
expression level (1.a) and the ratio of luciferase 
expression (1.b) were measured. The highest and the 
best expression levels under the condition of 1.5104 
effector to 1104 reporter cells ratio (1.5/1) were 
obtained. The more increase in effector cell number, the 
higher expression level was observed. This relationship 
was faded with an increase in the number of the effector 
cells to more than 15.000 where a decline in luciferase 
level was also observed.  
A matrix containing the reporter cell with the effector 
cells and with the Jurkat cell (as the negative control)  
separately was cultivated. After 48 hr incubation, the 
luciferase expression level (a) and the ratio of luciferase 
expression (b) were measured. a) The mean of the 
relative luciferase expression level (RLU×103) from the 
three experiments in two different days was presented. 
The best luciferase expression was bolded. b) The test to 
control the luciferase expression ratio (of Table1.a 
experiments) was calculated. 
The mean of luciferase expression level by reporter 
cell versus HTLV-1 (MT2 and HuT-102) producing cell, 
HTLV-1 free cell (Jurkat), was measured. HuT-102 and 
MT2 effector cells caused an increase in the luciferase 
expression level by 3x and 2.5x, respectively, while the 
Jurkat cell decreased it by 0.9 x. 
 
 
 
 
 
a) 
 
b) 
 
Figure 4. The viability of reporter and Jurkat cells were measured after 72 hr co-cultured in the absence(a) and presence(b) of drugs Arsenic 
(1 μmol/ml), and Interferon α2 (1000 Iu/ml)) using flow cytometry method 
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Table 1. Optimization of the expression level, affected by different numbers of effector-to-reporter cells                                                             
 
a) 
30000 25000 20000 15000 10000 5000  Effector    ➔ 
                  Reporter 
566 ±33 710 ±28 802 ±27 798 ±24 653 ± 43 469 ±21 5000 
605 ±61 808  ±32 862 ±38 968 ±27 895 ±44 553 ±36 10000 
575 ±69 822 ±47 768 ±26 939 ±34 917 ±41 674 ±28 15000 
618 ±30 663 ±48 765 ±22 732 ±49 699 ±26 733 ±32 20000 
b) 
 
 
30000 25000 20000 15000 10000 5000  Effector  ➔   
                  Reporter 
2.1   ±  0.14 2.54 ±  0.11 2.82  ±  0.1 2.78 ±  0.09 2.4  ±  0.18 1.59 ±  0.07 5000 
2.24 ±  0.26 2.76 ±  0.12 2.86 ±  0.14 3.2    ±  0.1 3   ±  0.16 1.72 ±  0.12 10000 
1.84 ±  0.25 2.45 ±  0.16 2.3   ±  0.09 2.82 ±  0.11 2.7  ±  0.14 1.93 ±  0.09 15000 
1.67 ±  0.09 1.73 ±  0.14 2     ±  0.06 1.86 ±  0.14 1.81 ±  0.07 1.84 ±  0.09 20000 
 
Evaluating the application of the reporter cell in 
drug screening against HTLV-1 virus 
The effect of different values of Arsenic trioxide 
(0.5-2 µmol/ml) and Interferon alfa (500-2000 Iu/ml) 
on the reporter and Jurkat cells, after 72 hr, was 
calculated based on the cell counting and the 
corrected viability percent of the cells to the control. 
Those drug densities, in which more than 90% of cells 
remained viable, were selected for the next test (i.e. 
the effect of which on the HTLV-1 infected cell and on 
the virus itself), and subsequently for the luciferase 
expression. These densities included: Arsenic (1 
µmol/ml), and Interferon (1000 Iu/ml). By adding the 
(above) mentioned densities of these two medicines to 
the cellular cultivation media, the hybrid effect of them 
on the reporter, Jurkat, and effector cells was measured 
by using the flow cytometry method (Figure 4). 
 
The effect of the new combination therapy against 
HTLV-1 on the luciferase expression of the reporter 
cell 
The luciferase expression level after co-culture of 
the 72 hr treated effector cells (Hut-102, MT2) with 
the reporter cells, considerably decreased in the 
presence of drugs (P-value =0.005). In terms of the 
Hut-102 and MT2 cells, these expressions decreased 
to less than half (from 32×5 to 14.1×3) and about 0.68 
(from 12.9×1.4 to 8.7×1.7), respectively, in comparison to 
the cells which received no drugs. 
 
The correlation between the luciferase expression 
and the HTLV-1 p19 antigen 
P19 antigen is a HTLV-1 matrix antigen which 
determines the quantitative measurement of the viral 
particle and its reproduction. Therefore, by seeking 
this antigen in cellular cultivation, the effect of the 
drug on the formation of viral particle versus the 
control cell can be quantitatively observed. The  level 
of p19 antigen, after the cultivation of the effector 
cells (MT2, Hut-102), considerably decreased in the 
presence of drugs (P-value =0.005 & P-value =0.032). 
Furthermore, in terms of Hut-102 and MT2, this              
level declined to less than 0.3 (from 645 ×21Pg/ml to  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The correlation between ELISA p19 and luciferase 
expression (instead of luciferase experssion, the ratio of Luciferase 
to GFP experssions was used to normalize the luciferase expression, 
shown on vertical axis)( P-value =0.002, and R=0.932) 
 
172×25 Pg/ml) and lower than 0.55 (from 357 Pg/ml              
to 195 Pg/ml), respectively, in comparison with the             
cells which received no drugs. Meanwhile a strong 
correlation between ELISA and the luciferase expression 
was observed (P-value =0.002, and R=0.932) (Figure 5). 
 
Assessment the amount of the intercellular HTLV-
1RNA, using the real-time RT-PCR 
The level of RNA expression after culturing the 
effector cells (Hut-102 and MT2) in the presence of 
medicine was measured, by using the Tax gene 
specific primer. For normalization of the experiment, 
GAPDH primers (Housekeeping gene) were used. By 
incorporation of the ΔΔCt technique, a decline in the 
expression level was observed in MT2 cells (1.22 
cycles). However, this decline was not observed in Hut-
102 cells.  
 
Discussion 
Due to the necessity of developing a biological 
system for HTLV-1, a unique HTLV-1 reporter cell line 
with two reporter vectors was designed in order to 
monitor HTLV-1 infectivity and the cell viability 
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simultaneously. At first, these two reporter vectors 
were constructed and tested, and then BHK-21 cell 
was stably transfected by them. The EGFP reporter 
vector and the luciferase reporter vector confer 
Hygromycin and Geniticin (G418) resistance to the 
transfected cells respectively. Therefore, the selection 
clonies of the BHK-EGFP-HTLVLTR-Luc cells were 
performed by culturing them in the presence of 
hygromycin and geniticin.  
By investigating the 236 G418 resistance clones,             
it was unfortunately determined that in most cases, 
luciferase gene or the virus promoter was turned off. 
This can be due to the vector integration in hetero-
chromatin regions of the genome. There are reasons 
such as methylation in the critical regions of the 
promoter, the removal of the vector from the cell for 
any reason, or aberrant vector cut off at the time of 
integration can also be mentioned. In addition, it is 
said that in the spontaneous selection, the reporter 
resistant cells grow faster than the resistance gene 
carrying cells. Unfortunately, other groups of clones 
were the cells that despite of very high luciferase 
inductive expression had the high background level of 
expression too. This caused a very small difference 
between the test and control groups, leading to an 
insignificant test interpretation. As mentioned earlier, 
the virus promoter can be affected by the cellular 
signaling pathways. On the other hand, regarding the 
similarity between TRE and cyclic AMP response 
element (aka CRE)(30), there is a possibility that the 
virus promoter gets affected by the cellular signaling 
pathways (31). This possibility can be associated with 
the luciferase background expression without an 
induction by the Tax protein. However, the background 
level of expression in stabilized cells was to the extent 
that the expression difference between the test and 
control cells declined from 50 folds, in temporary 
transfer (32), to about 3 folds, in permanent transfer. 
This is due to the fact that in Tax protein, 
transactivation of the promoter is done through 
binding to CBP/P300, CREB, and P/CAF proteins. 
Okada and Jeang showed that the different values of 
these proteins had so greater impact on the activity of 
the promoters in stabilized cells than in cells to which 
the virus promoter was temporarily transferred (31).  
 The first reporter cell line for HTLV-1 was 
established using HeLa cell by Copeland et al., based 
on the HTLV-1LTR (33). The induction of the β-
galactosidase expression in this cell was done with the 
Tax protein, but simultaneous cultivation of this cell 
with MT2 did not result in reporter expression. While, 
an increase was observed in reporter expression in 
the cell established in this design, in the presence of 
the Tax protein, as well as MT2 and Hut-102 cells. 
After Copeland et al. Astier-Gin et al. developed LTR-
LacZ based cells for HTLV-1(21). They performed the 
experiments in a 25cm2 cell cultivation flask with, at 
least, 1.5×105 reporter cells. Statistically, he reported 
the minimum number of effector cells required for the 
induction of the reporter cell equal to a ratio of 13-22 
to 1 (13-22/1). However, in this study, the best ratio 
of  the effector to reporter was achieved equal to 
1.5×104/104 (i.e. 1.5/1), although, the sensitivity of 
the established cell was observed with less than 2000 
effector cells (data not shown). The developed cell 
was easily used by its cultivation in 96-well micro 
plate, using 104 cells. This is the greatest advantage of 
using this cell vastly in order to achieve such goals as 
drug screening (22). 
In contrast to HIV, in HTLV-1 infection, viremia is 
essentially a cell-based cytoviremia (40, 41). Therefore, 
to develop the infection, co-culture of the virus 
producing cells is used (42). In order to investigate 
the specificity of the cells which were developed in 
this study, two HTLV-1 producing cell lines were used. 
Moreover, Jurkat cell was employed as a negative 
control and for normalization of the co-culture of two 
cells. The co-culture of Hut-102 and MT2 cells, like 
Tax protein, increased the luciferase expression; 
while, the co-culture with Jurkat cell decreased the 
background level of expression. This decline could be 
due to the consumption of nutrients by this cell and 
the subsequent reduction of the reporter cell metabolism, 
leading to a decreased level of luciferase expression.  
In all of the mentioned studies on HTLV-1, the 
established cells included only one reporter. In this 
research, a second EGFP-based reporter is permanently 
expressed, using the SV40 promoter. In addition, EGFP 
expression can be a criterion for the cell number in the 
tests.  As it was shown, the expression of this reporter 
was in direct, linear relationship with a cell number over 
20×103 cells. The application of this specification could 
be advantageous in the drug screening trials, where 
other effects of drug on the reporter cell could be 
distinguished from the effects on the effector cell or 
virus. 
Although, there was a number of commercial methods 
for drug resistance phenotyping in the case of HIV (34), 
Chiba-Mizutani et al. developed a system capable of 
virus tracking and drug-induced cytotoxicity, using a 
murine leukemia virus (MaRBLE) transformed T-
lymphocyte cell line, as well as two luciferase reporter 
genes. The introduction of luciferase to the second 
reporter is an advantage of that cell compared to the 
method used in the present study; however, in this 
design, the SV40 promoter was used, instead of CMV, to 
ease the effect of the first reporter on the cellular energy. 
Regarding that there are confirmed anti-HIV drugs, his 
group had more maneuverability for evaluating the 
established system (17). In this study, since there were 
no confirmed anti-HTLV-1 drugs (35, 36, 40-42), the 
medicine which was used in a previous research was 
employed (29, 37, 38).  
The effects of drug on the virus and the effector cell 
were measured by investigating the luciferase expression 
in the reporter cell (considering the EGFP expression 
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and the number of viable cells), in comparison with 
ELISA p19 antigen of HTLV-1, and Real-time RT-PCR. 
The results suggested a strong correlation between 
ELISA p19 and luciferase expression (P-value= 0.002, 
and R= 0.932). This means that the effect of drug on the 
virus reduced the extracellular particles (ELISA, p19), 
and so this decline was also seen in the luciferase 
expression because the reporter cell had been affected 
by the lower virus number. The results from the real-
time RT-PCR test were different, in a way that although 
a slight decline was seen in the level of viral RNA of MT2 
cell, this decline was not observed in Hut-102 cells. In 
other words, pharmaceutical composition had no effect 
on the Tax expression, and in fact on the transcription of 
the intercellular provirus regarding its comparison with 
GAPDH gene, which is a function of drug effects on             
the cell. In result, these drugs, especially in terms of Hut-
102 cell, have not caused transcription decline, but               
it seems they have mostly decreased the virus release, 
attachment, penetration, virus insertion, and/or reverse 
transcription and integration mechanisms in the 
reporter cells. Diagnosis of the drug impact on these last 
mechanisms is not possible with ELISA, indicating the 
superiority of this system over ELISA.As mentioned 
before; drugs caused a decrease in the number of the 
virus released from the cell. Regarding that the 
interferon was a drug used and previous studies showed 
its role in releasing the virus from the cell, this was an 
expectable effect (39). On the other hand, these results 
revealed the superiority of the present study over the 
molecular methods from different dimensions. 
 
Conclusion  
Despite this, although the medium-throughput 
constructed system are cost effective and advantageous 
for performing basic and pharmaceutical studies, it is 
associated with a number of disadvantages such as the 
need for facilities including cellular cultivation labora-
tory and costly devices like luminometer. 
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